A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Case-based Education
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.
January 19, 2023: Zanubrutinib received FDA approval for CLL/SLL.
January 27, 2023: Pirtobrutinib received FDA approval for mantle cell lymphoma.
December 1, 2023: Pirtobrutinib received accelerated FDA approval for CLL/SLL.
Faculty: Nitin Jain, MD, Jacqueline Barrientos, MD, MS, Catherine Coombs, MD, Sameer Parikh, MD, MBBS
Release Date:
Expiration Date: January 31, 2024
CME/CE is no longer available for this activity
